Cencora, Inc. (COR)

Cencora's stock has experienced significant growth over the past six months. Analyst upgrades and increased price targets have contributed to a strong market performance outlook. The company's Q2 CY2025 results surpassed revenue expectations, and the acquisition of Retina Consultants of America and focus on GLP-1 drugs have strengthened its specialty solutions. Moody's Ratings upgraded Cencora's senior unsecured ratings.

Cencora operates in the healthcare sector, which generally experiences stable demand. The pharmaceutical sales in the U.S. market are anticipated to grow, indicating a consistent underlying demand for its core distribution services. The rising demand for GLP-1 drugs has also contributed to topline growth. Specific patterns or significant seasonal fluctuations in demand for its products and services are not explicitly highlighted as a major factor impacting its business operations.

Cencora, Inc., formerly AmerisourceBergen Corporation, is a global healthcare solutions company established in 2001. The company operates within the pharmaceutical distribution and solutions industry, distributing pharmaceuticals and providing pharmacy solutions and manufacturer services. Cencora offers services such as supply chain optimization, patient services, pharmaceutical consulting, technology solutions, and global commercialization services, and also has an Animal Health segment.

Cencora is headquartered in Conshohocken, Pennsylvania, and operates in over 50 countries. It serves thousands of customers, including retail pharmacies, hospital systems, physician offices, and specialty pharmacies, both in the United States and internationally. The company provides pharmaceutical wholesale, related services, and specialty transportation and logistics services globally.

Cencora's brand reputation has been influenced by its rebranding and corporate social responsibility efforts, as well as historical challenges. The company rebranded from AmerisourceBergen to Cencora in August 2023. Cencora emphasizes its commitment to sustainability and social responsibility through the Cencora Impact Foundation. In May 2024, Cencora disclosed a cyber incident that exposed patient information.

Cencora has 2403 institutional owners and shareholders holding a total of 215,785,390 shares. Institutional Investors own approximately 54.74% of the company's stock, Insiders own 6.78%, and Public Companies and Individual Investors own 38.48%. Major institutional shareholders include Vanguard Group Inc and BlackRock, Inc. Individual investor ownership is also significant, with retail investors holding approximately 38.48% of the stock.